  |
Zyvox (linezolid) or Methylene Blue: Potential Drug Interaction with Serotonergic Psychiatric Medications
MedWatch updated our previous (07/26/2011) safety alerts on the potential drug interaction between linezolid or methylene blue and serotonergic psychiatric medications.
Not all serotonergic psychiatric drugs have an equal capacity to cause serotonin syndrome with linezolid or methylene blue. Most cases from the FDA's Adverse Event Reporting System (AERS) of serotonin syndrome associated with linezolid occurred in patients taking specific serotonergic psychiatric drugs, including selective serotonin reuptake inhibitors (SSRI), or serotonin norepinephrine reuptake inhibitors (SNRI). Most cases from AERS of serotonin syndrome associated with methylene blue occurred in patients taking SSRIs, SNRIs, or clomipramine.
It is unclear at this time whether linezolid or methylene blue administration in patients receiving other psychiatric drugs with lesser degrees of serotonergic activity poses a comparable risk.
Read the MedWatch safety alert UPDATES:
Zyvox (linezolid): http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265479.htm
Methylene Blue: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265476.htm
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
